Regulatory T cells (Tregs) are critical for the maintenance of peripheral immunological self-tolerance. Armed with potent suppressive functional programs, they regulate diverse immune responses in various pathological conditions to maintain immune homeostasis and ensure measured responses to mitigate collateral damage to normal tissues. This important role however is construed to impede anti-tumor immune-orchestrated responses due to the nature of many tumor-associated antigens which while often expressed in aberrant forms, are still mostly self-antigens.
Over the last decades, our understanding of the immunobiology of Tregs in health and disease have improved considerably. However, there still remains much to be understood with respect to the contribution of Tregs to immune dysfunction in malignancies.
In this regard, this Research Topic will focus on Original Research, Perspective, and Review articles highlighting a number of important aspects of Tregs in a cancer setting. Topic areas of interest include but are not limited to:
- Current understanding of the role of Tregs in solid and blood cancers
- Treg contribution to impairment of other tumor-infiltrating immune cell subsets and associated mechanisms/modules underlying their inhibitory functions
- Phenotypically and functionally distinct clonal populations of Tregs in cancer
- Immunosuppressive T cell populations described in cancer settings that are of CD4+ and CD8+ T cell lineage and which are distinct from the prototypical CD4+CD25+Foxp3+ cells
- Molecular control of Treg stability, differentiation, and function
- Immunogenomic and epigenetic landscape of tumor associated Tregs
- Metabolic programming and adaptations of tumor infiltrating Tregs relative to their peripheral counterparts
- Treg-centric approaches to achieve quantitative disruption or functional impairment of tumor-infiltrating Tregs as a strategy to support therapeutic outcomes in cancer
- Clinical trials in which agents that directly or indirectly target Tregs were utilized and observed outcomes
- Perspectives and opinions on Treg-targeting strategies as a rational partner approach in novel combinatorial immunotherapy strategies
Regulatory T cells (Tregs) are critical for the maintenance of peripheral immunological self-tolerance. Armed with potent suppressive functional programs, they regulate diverse immune responses in various pathological conditions to maintain immune homeostasis and ensure measured responses to mitigate collateral damage to normal tissues. This important role however is construed to impede anti-tumor immune-orchestrated responses due to the nature of many tumor-associated antigens which while often expressed in aberrant forms, are still mostly self-antigens.
Over the last decades, our understanding of the immunobiology of Tregs in health and disease have improved considerably. However, there still remains much to be understood with respect to the contribution of Tregs to immune dysfunction in malignancies.
In this regard, this Research Topic will focus on Original Research, Perspective, and Review articles highlighting a number of important aspects of Tregs in a cancer setting. Topic areas of interest include but are not limited to:
- Current understanding of the role of Tregs in solid and blood cancers
- Treg contribution to impairment of other tumor-infiltrating immune cell subsets and associated mechanisms/modules underlying their inhibitory functions
- Phenotypically and functionally distinct clonal populations of Tregs in cancer
- Immunosuppressive T cell populations described in cancer settings that are of CD4+ and CD8+ T cell lineage and which are distinct from the prototypical CD4+CD25+Foxp3+ cells
- Molecular control of Treg stability, differentiation, and function
- Immunogenomic and epigenetic landscape of tumor associated Tregs
- Metabolic programming and adaptations of tumor infiltrating Tregs relative to their peripheral counterparts
- Treg-centric approaches to achieve quantitative disruption or functional impairment of tumor-infiltrating Tregs as a strategy to support therapeutic outcomes in cancer
- Clinical trials in which agents that directly or indirectly target Tregs were utilized and observed outcomes
- Perspectives and opinions on Treg-targeting strategies as a rational partner approach in novel combinatorial immunotherapy strategies